Respiratory Drug Delivery Devices

Respiratory Drug Delivery Devices Market Outlook

The global respiratory drug delivery devices market is anticipated to reach approximately USD 50 billion by 2035, growing at a notable compound annual growth rate (CAGR) of around 8.5% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), alongside the heightened awareness regarding the efficacy of medication delivery directly to the lungs. Additionally, the rise in the aging population and the demand for innovative therapies have spurred the development and acceptance of advanced drug delivery devices that allow for enhanced therapeutic outcomes. Moreover, technological advancements in nebulizers and inhalers, coupled with the growing number of patients opting for home healthcare solutions, further contribute to the market expansion.

Growth Factor of the Market

The respiratory drug delivery devices market is primarily driven by the increasing incidence of respiratory ailments globally, which is coupled with the rising awareness among patients and healthcare professionals about the benefits of targeted drug delivery systems. Furthermore, a growing emphasis on preventive healthcare has led to the adoption of these devices, as they offer quick relief and effective management of chronic diseases. The surge in the number of patients suffering from allergies, environmental pollution, and smoking-related conditions has necessitated the need for effective respiratory drug delivery solutions. In addition to these factors, advancements in technology have led to the development of more efficient and user-friendly devices, which have made them more accessible to patients. The integration of smart technologies into respiratory devices is also improving patient compliance and monitoring, further driving market growth.

Key Highlights of the Market

• The market is projected to exhibit a robust CAGR of 8.5% over the forecast period.
• Increasing prevalence of asthma and COPD among populations worldwide is a significant growth driver.
• Technological advancements and innovations in respiratory drug delivery devices are enhancing patient experience and outcomes.
• The demand for home healthcare solutions is on the rise, contributing to market expansion.
• Emerging markets are expected to witness substantial growth owing to improving healthcare infrastructure.

By Product Type

Inhalers:

Inhalers represent a significant segment within the respiratory drug delivery devices market, primarily due to their portability and ease of use. They are designed to deliver medication directly to the lungs, providing an effective method for managing respiratory conditions. Inhalers can be classified into various types, including metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), which cater to different patient needs. The increasing prevalence of respiratory diseases, coupled with the growing awareness of inhalation therapy, is driving the adoption of inhalers. Furthermore, ongoing innovations aimed at improving the efficacy and user-friendliness of inhalers are expected to bolster their market share significantly over the forecast period.

Nebulizers:

Nebulizers are medical devices that convert liquid medication into aerosolized mist, making it easier for patients to inhale. They are particularly beneficial for individuals with severe respiratory conditions, particularly children and elderly patients who may struggle with traditional inhalers. The growing acceptance of nebulizers in both clinical and home settings has expanded their usage. As the market evolves, newer nebulization technologies, such as vibrating mesh nebulizers, are being developed to enhance drug delivery efficiency and patient compliance. The increasing focus on home healthcare solutions, especially post-pandemic, is expected to drive the growth of the nebulizer segment significantly.

Dry Powder Inhalers:

Dry powder inhalers (DPIs) are gaining momentum within the respiratory drug delivery market due to their convenience, portability, and the absence of propellants. DPIs require patients to inhale forcefully to receive medication, thus relying on the user's effort. This segment is witnessing growth as awareness of asthma and COPD management rises, alongside an emphasis on patient-centric devices. The DPIs are recognized for their ability to ensure accurate drug delivery with minimal side effects, which is appealing to both healthcare providers and patients. Moreover, as manufacturers invest in developing advanced DPIs with additional features such as dose counters and improved ergonomics, market penetration is expected to rise.

Metered Dose Inhalers:

Metered-dose inhalers (MDIs) have been a staple in respiratory drug delivery for decades, primarily due to their effectiveness and widespread availability. These devices can deliver a precise dose of medication with each actuation, making them highly reliable for managing conditions such as asthma and COPD. However, the market for MDIs faces stiff competition from DPIs and nebulizers which are perceived to be easier to use. The inclusion of integrated spacing devices and combination therapies in MDIs is enhancing their appeal and market share. As the healthcare system strives for more efficient drug delivery systems, MDIs are evolving to incorporate smart technology features that improve patient adherence and monitoring.

Soft Mist Inhalers:

Soft mist inhalers (SMIs) are emerging as a novel option in the respiratory drug delivery devices market, offering an innovative approach to medication delivery. SMIs generate a slow-moving mist that allows for a more efficient uptake of medication in the lungs with minimal coordination required from the patient. This feature is particularly beneficial for those who struggle with traditional inhalers. The unique design and delivery mechanism of SMIs contribute to improved patient experience and increased compliance. With the growing focus on developing user-friendly devices, the SMI segment is anticipated to witness considerable growth as it addresses common challenges associated with traditional inhalers.

By Application

Asthma:

Asthma is one of the leading applications driving the respiratory drug delivery devices market. The increasing prevalence of asthma, fueled by factors such as air pollution, allergens, and genetic predisposition, has heightened the need for effective management strategies. Drug delivery devices play a vital role in controlling asthma symptoms and preventing exacerbations. The market is witnessing growth as healthcare providers increasingly recommend inhalers and nebulizers as first-line treatments. Additionally, the development of combination therapies that incorporate multiple medications into single inhalers is further enhancing treatment options for asthma patients.

COPD:

Chronic obstructive pulmonary disease (COPD) is another significant application within the respiratory drug delivery devices market. With a rising global burden of COPD attributed to smoking and environmental factors, there is a pressing demand for efficient drug delivery systems tailored to manage this chronic condition. The increasing awareness of COPD and its management through inhalers and nebulizers is pushing the market forward. Furthermore, advancements in technology aimed at improving drug efficiency and patient adherence are facilitating better outcomes for COPD patients, thereby solidifying the segment's growth.

Cystic Fibrosis:

Cystic fibrosis (CF) is a genetic disorder affecting the lungs, leading to the production of thick mucus that can obstruct airways. The management of CF often requires complex treatment regimens, including the use of inhaled medications. As a result, respiratory drug delivery devices play a crucial role in delivering therapies directly to the lungs, improving patient outcomes. The rising prevalence of cystic fibrosis, along with advancements in nebulization technologies that enhance medication delivery, is propelling this segment's growth. The focus on personalized medicine and targeted therapies in CF management is expected to further increase the demand for specialized respiratory devices.

Allergic Rhinitis:

Allergic rhinitis is a prevalent condition that affects millions worldwide, leading to symptoms like sneezing, congestion, and itchy eyes. The demand for effective management strategies has prompted a growing interest in respiratory drug delivery devices. Inhalers and nasal sprays are commonly used to alleviate symptoms associated with allergic rhinitis, making them essential tools for patients. The market is witnessing growth due to an increase in environmental allergens and changing lifestyles, which contribute to the rising incidence of allergic rhinitis. Continuous innovations in delivery devices aimed at improving efficacy and patient compliance are expected to drive this segment further.

Others:

This category includes various respiratory conditions that may require drug delivery devices, such as bronchitis, pneumonia, and obstructive sleep apnea. While these conditions may not be as prevalent as asthma or COPD, they still contribute to the overall market demand for respiratory drug delivery solutions. The expanding range of available treatments and the increasing recognition of the importance of effective medication delivery are leading to growth in this segment. Ongoing research and development in respiratory therapies tailored to these conditions are expected to further support the demand for innovative delivery devices.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as critical points for distributing respiratory drug delivery devices, providing healthcare professionals and patients access to a wide range of medications and devices. Within this segment, the increasing number of patients being treated for respiratory conditions in hospitals is driving demand for inhalers, nebulizers, and other delivery devices. Hospital pharmacies are also at the forefront of introducing new therapies and devices to healthcare providers, thereby influencing treatment practices. The growing emphasis on patient care and the provision of personalized medications are further boosting the role of hospital pharmacies in the distribution of respiratory devices.

Retail Pharmacies:

Retail pharmacies play a vital role in the distribution of respiratory drug delivery devices, offering convenient access for patients seeking over-the-counter and prescription medications. The increasing awareness of respiratory diseases and the availability of devices at retail locations contribute to the segment's growth. Retail pharmacies often provide essential educational resources and consultations to patients, guiding them on the proper use of inhalers and nebulizers. Additionally, with the rise of health-conscious consumers, retail pharmacies are increasingly stocking innovative respiratory devices, thereby enhancing their market presence.

Online Stores:

The online distribution channel for respiratory drug delivery devices is rapidly gaining traction, driven by the increasing preference for online shopping among consumers. The convenience and accessibility of purchasing devices through e-commerce platforms have made it easier for patients to obtain necessary medications and equipment. Online stores often provide a wider selection of products, competitive pricing, and the ability for patients to compare different devices. Additionally, the COVID-19 pandemic has accelerated the shift towards digital health solutions, prompting more consumers to seek online options for respiratory drug delivery devices. This trend is expected to continue, resulting in significant market growth.

By Technology

Manual Devices:

Manual devices in respiratory drug delivery play a crucial role in patient management, allowing users to control the delivery of medication through their breathing patterns. These devices require specific inhalation techniques for effective drug delivery, which can sometimes be a barrier to proper usage, especially among certain demographics. While manual devices are widely used, their efficacy heavily relies on patient compliance and technique, leading to a push for more user-friendly alternatives. Nevertheless, they continue to be an essential segment within the market due to their simplicity and reliability, particularly for patients familiar with their operation.

Digitally Operated Devices:

Digitally operated devices represent a significant advancement in respiratory drug delivery technology, integrating smart features to enhance patient monitoring and adherence. These devices often come equipped with connectivity capabilities that allow healthcare providers to track medication use and monitor patients remotely. The incorporation of digital technology is transforming how respiratory therapies are managed, providing real-time data and insights that improve treatment outcomes. As digital health continues to gain prominence, the market for digitally operated respiratory devices is expected to expand substantially, driven by the demand for personalized and connected healthcare solutions.

Breath-Actuated Devices:

Breath-actuated devices are designed to deliver medication automatically upon inhalation, eliminating the need for precise timing and coordination from the user. This feature significantly enhances patient convenience, especially for those who may struggle with traditional inhalers. The ease of use associated with breath-actuated devices is encouraging their adoption among patients with varying levels of experience in managing respiratory conditions. As awareness of the benefits of these devices grows, manufacturers are focused on developing more advanced breath-actuated systems that improve drug delivery efficiency, further propelling market growth.

Spacer Devices:

Spacer devices are accessories used in conjunction with inhalers to improve drug delivery efficiency. They allow medication to be released into an extended chamber, giving patients more time to inhale the medication effectively. This technology is particularly beneficial for children and elderly patients who may require assistance with inhalation techniques. The increasing recognition of the importance of optimizing drug delivery for better patient outcomes is leading to greater adoption of spacer devices. As advancements in spacer technology continue, including the development of smart spacers that track usage and technique, the segment is expected to experience notable growth.

Vibrating Mesh Technology:

Vibrating mesh technology is at the forefront of innovation in nebulizer design, offering an efficient method for aerosolizing liquid medications into fine particles for inhalation. This technology enhances drug delivery by producing a consistent mist that is easily inhaled by patients. The advantages of vibrating mesh nebulizers, including reduced medication waste, shorter treatment times, and portability, are driving their increasing acceptance among patients and healthcare providers alike. As research continues to validate the efficacy of this technology, the market for vibrating mesh devices is expected to expand, particularly in home healthcare settings where convenience and efficiency are paramount.

By Region

The North American respiratory drug delivery devices market is projected to dominate the global landscape, accounting for approximately 40% of total market share by 2035. The high prevalence of respiratory diseases such as asthma and COPD, along with advanced healthcare infrastructure, significantly contributes to this dominance. Additionally, the presence of key market players and a strong emphasis on innovation and research further bolster North America's leading position. Moreover, the region is expected to grow at a CAGR of around 8.2%, driven by the increasing adoption of home healthcare solutions and advancements in drug delivery technologies.

Europe is another vital market for respiratory drug delivery devices, holding an estimated 30% share of the global market by 2035. Factors such as rising awareness about respiratory diseases, increased healthcare expenditure, and the growing aging population have spurred market growth in the region. Furthermore, European countries are focusing on improving healthcare access and investing in advanced drug delivery technologies. The Asia Pacific region is also projected to witness significant growth, with a CAGR of approximately 9.0% during the forecast period, driven by rising pollution levels, increasing healthcare awareness, and enhanced access to respiratory therapies.

Opportunities

As the respiratory drug delivery devices market matures, several opportunities for growth and innovation are emerging. One of the most notable opportunities lies in the development of personalized medicine tailored specifically for respiratory conditions. With advancements in genetic research and diagnostics, healthcare providers can create customized treatment plans that optimize medication delivery based on individual patient profiles. This approach is expected to not only improve patient outcomes but also increase adherence to treatment regimens, thereby enhancing the overall effectiveness of respiratory therapies. Additionally, the rise of telemedicine and remote patient monitoring offers a unique opportunity for device manufacturers to integrate their products with digital health platforms, enabling real-time tracking of patient usage and medication adherence.

Another significant opportunity lies in the expansion into emerging markets, where the demand for respiratory drug delivery devices is on the rise. As healthcare infrastructure improves and access to medications increases in developing regions, there is potential for substantial growth in device adoption. Manufacturers can capitalize on this trend by tailoring products to meet the specific needs and preferences of these markets, including affordability and ease of use. Additionally, partnerships with local healthcare providers and organizations can facilitate market entry and enhance brand visibility. The increasing focus on preventive healthcare and home healthcare solutions presents further opportunities, as more patients seek convenient and effective methods to manage their respiratory conditions.

Threats

The respiratory drug delivery devices market faces several threats that could hinder growth and adoption. One of the primary threats is the increasing competition from alternative treatment modalities and therapies that do not rely on traditional drug delivery methods. For instance, biologic therapies and other advanced treatment options are gaining traction, which could lead to a shift away from conventional inhalers and nebulizers. Additionally, rising concerns over the safety and efficacy of certain respiratory devices may also impact market growth, particularly if there are reports of adverse effects associated with specific products. Furthermore, stringent regulatory requirements and lengthy approval processes can pose challenges for manufacturers aiming to introduce new devices into the market.

Another significant threat is the potential for supply chain disruptions, which can adversely affect the availability of respiratory drug delivery devices. Global events, such as pandemics or geopolitical tensions, can lead to shortages of raw materials and components necessary for device production. Moreover, growing concerns regarding environmental impacts related to disposable inhalers and devices may lead to regulatory scrutiny and shifts in consumer preferences toward more sustainable options. Manufacturers will need to adapt to these evolving expectations and ensure compliance with environmental regulations to maintain market share.

Competitor Outlook

• GlaxoSmithKline plc
• Novartis AG
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Chiesi Farmaceutici S.p.A.
• Fresenius Kabi AG
• ResMed Inc.

The competitive landscape of the respiratory drug delivery devices market is characterized by several key players, each striving to establish a strong foothold in this rapidly evolving sector. Major pharmaceutical companies are investing heavily in research and development initiatives to innovate and enhance their product offerings. The competition is marked by a continuous influx of new entrants looking to capitalize on market opportunities, leading to a diverse range of products available to patients. Companies are also focusing on strategic collaborations and partnerships to bolster their market presence, enhance distribution networks, and improve access to their devices. As a result, innovation and differentiation based on technology and patient-centric features are becoming increasingly critical for success in this competitive environment.

Among the leading competitors, GlaxoSmithKline plc stands out with its extensive portfolio of inhalers and nebulizers, showcasing a commitment to addressing the diverse needs of respiratory patients. The company leverages its significant research capabilities to develop innovative therapies and delivery devices, including the integration of digital health technologies. Novartis AG has also made significant strides in the respiratory market, with a focus on personalized medicine and the development of biologic therapies. Their collaboration with various healthcare institutions enables them to enhance patient outcomes through tailored treatment approaches.

AstraZeneca plc is another prominent player in the respiratory drug delivery devices market, known for its robust pipeline of inhaled medications and advanced drug delivery systems. The company actively invests in digital solutions to improve patient adherence and monitoring, ensuring that their products cater to modern healthcare demands. Boehringer Ingelheim GmbH emphasizes continuous innovation, particularly in the realm of inhalation therapies, with a commitment to improving the efficacy and usability of their devices. The competitive landscape remains dynamic, with established companies and new entrants alike vying for a share of this lucrative market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Mylan N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 ResMed Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Fresenius Kabi AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Boehringer Ingelheim GmbH
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals PLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Chiesi Farmaceutici S.p.A.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Otsuka Pharmaceutical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Respiratory Drug Delivery Devices Market, By Technology
    • 6.1.1 Manual Devices
    • 6.1.2 Digitally Operated Devices
    • 6.1.3 Breath-Actuated Devices
    • 6.1.4 Spacer Devices
    • 6.1.5 Vibrating Mesh Technology
  • 6.2 Respiratory Drug Delivery Devices Market, By Application
    • 6.2.1 Asthma
    • 6.2.2 COPD
    • 6.2.3 Cystic Fibrosis
    • 6.2.4 Allergic Rhinitis
    • 6.2.5 Others
  • 6.3 Respiratory Drug Delivery Devices Market, By Product Type
    • 6.3.1 Inhalers
    • 6.3.2 Nebulizers
    • 6.3.3 Dry Powder Inhalers
    • 6.3.4 Metered Dose Inhalers
    • 6.3.5 Soft Mist Inhalers
  • 6.4 Respiratory Drug Delivery Devices Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Respiratory Drug Delivery Devices Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Respiratory Drug Delivery Devices market is categorized based on

By Product Type

• Inhalers
• Nebulizers
• Dry Powder Inhalers
• Metered Dose Inhalers
• Soft Mist Inhalers

By Application

• Asthma
• COPD
• Cystic Fibrosis
• Allergic Rhinitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

By Technology

• Manual Devices
• Digitally Operated Devices
• Breath-Actuated Devices
• Spacer Devices
• Vibrating Mesh Technology

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GlaxoSmithKline plc
• Novartis AG
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Chiesi Farmaceutici S.p.A.
• Fresenius Kabi AG
• ResMed Inc.